Voyager CFO Allison Dorval resigns; Julie Burek appointed CFO effective Nov 26, 2021

Voyager Therapeutics, Inc.

Allison Dorval resignation as CFO effective Nov 26, 2021, to pursue role at another company.
Dorval to enter separation agreement and consulting contract through Jan 14, 2022.
During consulting period, existing RSUs and stock options continue vesting as if employed.
Julie Burek, VP of Finance since Aug 2020, appointed principal financial and accounting officer.
Burek receives option for 25,000 shares effective Nov 26, 2021, and RSU for 13,500 shares effective Jan 1, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Allison Dorval

Chief Financial Officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2021-11-26
Successor: Julie Burek
Filed: November 19, 2021, 6:59 PM ET

Allison Dorval notified Voyager Therapeutics, Inc. (the "Company") of her resignation as Chief Financial Officer of the Company, effective November 26, 2021

Appointed

Julie Burek

principal financial officer and principal accounting officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2021-11-26
Filed: November 19, 2021, 6:59 PM ET

the board of directors of the Company (the "Board") has appointed Julie Burek to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allison Dorval resigned as Chief Financial Officer at Voyager Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Allison Dorval notified Voyager Therapeutics, Inc. (the "Company") of her resignation as Chief Financial Officer of the Company, effective November 26, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Burek was appointed as principal financial officer and principal accounting officer at Voyager Therapeutics, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

the board of directors of the Company (the "Board") has appointed Julie Burek to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Effective Date.

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-141614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.